-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analysts Issue Forecasts for NewAmsterdam Pharma's FY2027 Earnings (NASDAQ:NAMS)
Analysts Issue Forecasts for NewAmsterdam Pharma's FY2027 Earnings (NASDAQ:NAMS)
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Research analysts at William Blair issued their FY2027 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Monday, January 23rd. William Blair analyst M. Phipps expects that the company will earn ($0.16) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
Get NewAmsterdam Pharma alerts:Several other research analysts also recently commented on the company. Credit Suisse Group began coverage on NewAmsterdam Pharma in a research note on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a research report on Monday, December 19th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, SVB Leerink assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price objective on the stock.
NewAmsterdam Pharma Stock Up 20.0 %
Shares of NewAmsterdam Pharma stock opened at $13.56 on Thursday. NewAmsterdam Pharma has a 1 year low of $7.52 and a 1 year high of $32.88. The company's fifty day simple moving average is $10.37.NewAmsterdam Pharma Company Profile
(Get Rating)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
Recommended Stories
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Research analysts at William Blair issued their FY2027 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Monday, January 23rd. William Blair analyst M. Phipps expects that the company will earn ($0.16) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
新阿姆斯特丹製藥公司(NASDAQ:NAMS-獲取評級)— 威廉·布萊爾的研究分析師在 1 月 23 日(星期一)向客戶和投資者發布了對新阿姆斯特丹製藥公司的 FY2027 每股收益估計。威廉·布萊爾分析師 M. 菲普斯預計,該公司將在今年的每股收入(0.16 美元)。威廉·布萊爾(William Blair)目前的股票評級為「跑贏大市」。新阿姆斯特丹製藥公司目前全年收益的共識估計為每股 0.27 美元。
Several other research analysts also recently commented on the company. Credit Suisse Group began coverage on NewAmsterdam Pharma in a research note on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a research report on Monday, December 19th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, SVB Leerink assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price objective on the stock.
其他一些研究分析師最近還評論了該公司。瑞信集團開始覆蓋新阿姆斯特丹製藥公司在研究筆記上週五, 1 月 6 日.他們為該公司發布了「跑贏大市」評級和 21.00 美元的目標價格。富瑞金融集團於 12 月 19 日(星期一)在一份研究報告中開始對新阿姆斯特丹製藥公司的報導。他們對該股發出了「買入」評級和 24.00 美元的價格目標。最後, SVB Leerink 承擔了覆蓋新阿姆斯特丹製藥公司在週二的研究報告, 12 月 20 日.他們對該股發出了「跑贏大市」評級和 19.00 美元的價格目標。
NewAmsterdam Pharma Stock Up 20.0 %
新阿姆斯特丹製藥股票上漲 20.0%
NewAmsterdam Pharma Company Profile
新阿姆斯特丹製藥公司簡介
(Get Rating)
(取得評分)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
新阿姆斯特丹製藥公司 N.V. 是一家臨床階段的生物製藥公司,為患有低密度脂蛋白膽固醇(LDL-C)高風險的心血管疾病高風險患者開發口服非他汀類藥物。該公司的主要候選產品是 obicetrapib,這是一種口服,低劑量膽固醇酯轉移蛋白抑製劑,作為單一療法和 ezetimibe 的聯合療法,用於降低 LDL-C 並預防重大心血管不良事件的臨床試驗。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- 獲取有關新阿姆斯特丹製藥公司(NAMS)的研究報告的免費副本
- Shopify 清除了帶手柄的杯子底座:動力可以繼續嗎?
- 電子商務的未來:分析與新數據
- 雪佛龍以 750 億美元的股份回購令股東感到滿意
- 列維·施特勞斯是一個非常適合收入投資者
- 3 個有大上升空間的小型大寫字母
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收新阿姆斯特丹製藥日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關新阿姆斯特丹製藥公司及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧